本帖最后由 老马 于 2012-1-13 21:20 编辑 5 `! o' n9 b& e
' w" G/ [$ o% U) A! F0 M* d
爱必妥和阿瓦斯丁的比较
* {; W& ^- p: x% _ E
$ I1 X6 E( L* o1 Y
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/' x6 O8 X2 Q. f3 s
8 [9 ]: w/ t" _ Z* }( ]
8 v: H8 K* r1 a8 l2 {% I% m
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/& }7 E9 q8 R! T
==================================================
0 P3 N* Z! e$ i [( w; O2 U1 VOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)1 \% O9 u) Z t, Z% s8 k
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
2 q- R8 D: q+ p3 e# Z0 [3 i# ?Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
7 r2 {$ `5 E4 m$ o4 e5 [: |- J* y
|